Short Interest in ChromaDex Co. (NASDAQ:CDXC) Rises By 6.7%

ChromaDex Co. (NASDAQ:CDXC) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 2,070,000 shares, a growth of 6.7% from the December 15th total of 1,940,000 shares. Based on an average daily volume of 1,270,000 shares, the short-interest ratio is currently 1.6 days. Approximately 4.3% of the company’s stock are short sold.

Insider Activity

In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the transaction, the director now owns 244,179 shares in the company, valued at approximately $1,511,468.01. This represents a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 9.64% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CDXC. Geode Capital Management LLC boosted its holdings in ChromaDex by 1.6% during the third quarter. Geode Capital Management LLC now owns 1,149,592 shares of the company’s stock worth $4,197,000 after buying an additional 17,963 shares during the last quarter. State Street Corp increased its stake in ChromaDex by 11.3% in the third quarter. State Street Corp now owns 618,028 shares of the company’s stock valued at $2,256,000 after purchasing an additional 62,692 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of ChromaDex by 8.4% in the 2nd quarter. Renaissance Technologies LLC now owns 416,100 shares of the company’s stock valued at $1,136,000 after buying an additional 32,400 shares during the period. JPMorgan Chase & Co. raised its stake in ChromaDex by 11.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 331,916 shares of the company’s stock worth $1,211,000 after buying an additional 33,150 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in ChromaDex by 170.0% in the second quarter. Bank of New York Mellon Corp now owns 190,442 shares of the company’s stock valued at $520,000 after acquiring an additional 119,915 shares during the period. Institutional investors and hedge funds own 15.41% of the company’s stock.

ChromaDex Trading Up 5.1 %

Shares of ChromaDex stock traded up $0.29 during mid-day trading on Monday, reaching $5.94. 364,834 shares of the stock were exchanged, compared to its average volume of 436,868. The company has a market cap of $453.72 million, a price-to-earnings ratio of 594.59 and a beta of 2.21. ChromaDex has a fifty-two week low of $1.36 and a fifty-two week high of $7.97. The firm has a 50-day simple moving average of $6.34 and a 200 day simple moving average of $4.47.

ChromaDex (NASDAQ:CDXC) last released its quarterly earnings results on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. The firm had revenue of $25.58 million during the quarter, compared to analysts’ expectations of $23.70 million. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. During the same period last year, the firm posted ($0.01) EPS. On average, research analysts predict that ChromaDex will post 0.04 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Roth Mkm raised their target price on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. HC Wainwright increased their price objective on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, November 4th. Finally, StockNews.com cut shares of ChromaDex from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 15th.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.